OncoCyte (NASDAQ:OCX - Get Free Report) announced its earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02), Zacks reports. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The company had revenue of $2.14 million during the quarter, compared to analysts' expectations of $0.13 million.
OncoCyte Price Performance
Shares of NASDAQ OCX remained flat at $2.79 during trading on Friday. The stock had a trading volume of 52,664 shares, compared to its average volume of 57,444. OncoCyte has a 12 month low of $1.92 and a 12 month high of $4.75. The stock has a market capitalization of $79.79 million, a PE ratio of -0.79 and a beta of 0.95. The business's fifty day simple moving average is $3.06 and its 200-day simple moving average is $2.69.
Analyst Ratings Changes
Several research analysts have weighed in on the company. StockNews.com assumed coverage on OncoCyte in a research note on Sunday, April 6th. They issued a "sell" rating on the stock. Stephens restated an "equal weight" rating and issued a $4.00 price target on shares of OncoCyte in a research note on Tuesday, March 25th. Needham & Company LLC restated a "buy" rating and issued a $4.25 price target on shares of OncoCyte in a research note on Tuesday. Finally, Lake Street Capital initiated coverage on OncoCyte in a research note on Friday, March 28th. They issued a "buy" rating and a $5.00 price target on the stock.
Check Out Our Latest Stock Report on OCX
About OncoCyte
(
Get Free Report)
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
See Also
Before you consider OncoCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.
While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
